Welcome to our dedicated page for Capricor Therapeutics SEC filings (Ticker: CAPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Capricor Therapeutics filings document a Delaware biotechnology issuer developing cell and exosome-based therapeutics, including Deramiocel for Duchenne muscular dystrophy. Its 8-K reports record quarterly and annual financial results, FDA communications tied to the Deramiocel Biologics License Application, Regulation FD disclosures, and material-event reporting for litigation-related actions.
Proxy materials address board elections, executive compensation, equity awards, shareholder voting matters, and other governance disclosures. The filing record also identifies CAPR common stock, par value $0.001 per share, as a Nasdaq-listed security and provides formal disclosure around operating results, capital structure, and public-company status.
CAPRICOR THERAPEUTICS, INC. EVP and general counsel Karen Krasney reported an exercise-and-sell transaction in the company’s common stock. She sold 25,000 shares in an open-market sale on May 1, 2026 at a weighted average price of $31.7019 per share, under a pre-arranged Rule 10b5-1 trading plan.
On the same date, she exercised stock options to acquire 25,000 shares of common stock at an exercise price of $3.18 per share. Following these transactions, she directly holds 30,547 shares of Capricor common stock.
Capricor Therapeutics chief financial officer Anthony Bergmann executed a combined option exercise and share sale involving 25,000 shares of common stock. He exercised stock options to acquire 25,000 shares at $3.18 per share, then sold 25,000 shares in an open‑market transaction at a weighted average price of $31.7016 per share.
The sale was carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted in December 2025, meaning the trades were scheduled in advance. After these transactions, Bergmann holds 8,223 shares of common stock directly and 116,980 stock options with a $3.18 exercise price expiring in 2032.
Capricor Therapeutics, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders on June 4, 2026, to elect eight directors, ratify its independent auditor, hold advisory votes on executive pay and pay frequency, and approve a charter amendment for officer exculpation.
The meeting will be held in person at the company’s San Diego headquarters, with April 6, 2026 set as the record date for the 57,840,102 shares of common stock entitled to vote. The proxy statement details board composition and independence, committee structures, executive and director compensation, and stockholder proposal mechanics for future annual meetings.
It also describes significant commercial distribution agreements for Deramiocel with Nippon Shinyaku in the United States and Japan, including upfront and milestone payments and revenue-sharing terms, as well as the company’s equity incentive plans and insider trading, hedging and pledging policies.
CAPRICOR THERAPEUTICS, INC. director Karimah Es Sabar exercised stock options to acquire 7,529 shares of Common Stock at $3.18 per share and, on the same date, sold all 7,529 shares at $32.00 per share.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, indicating the transactions were scheduled in advance rather than timed opportunistically. Following these transactions, the reporting person held no Common Stock directly.
CAPR proposed sale notice: The filing lists 7,529 shares of Common Stock to be sold on 04/02/2026 in connection with an exercise of stock options for cash. It also reports recent 10b5-1 sales by Karimah Es Sabar of 53,735 and 61,265 shares on 04/01/2026 and 03/31/2026, respectively, with proceeds shown.
CAPRICOR THERAPEUTICS, INC. executive vice president and general counsel Karen Krasney reported an exercise-and-sell transaction in company stock. She exercised stock options covering a total of 25,000 shares of common stock at exercise prices of $1.39, $3.74 and $3.18 per share.
On the same day, she sold 25,000 shares of common stock at a weighted average price of $30.1174 per share, with individual trades ranging from $30.00 to $30.31. Following these transactions, she directly holds 30,547 shares of CAPRICOR common stock. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, indicating the timing was set in advance.
CAPRICOR THERAPEUTICS director Karimah Es Sabar exercised stock options and sold the resulting shares in two days of trading. On March 31, 2026 and April 1, 2026, she exercised options to acquire a total of 115,000 shares of common stock at an exercise price of $4.86 per share and then sold all 115,000 shares in open-market transactions at weighted average prices of $30.1680 and $31.0268, respectively. Following these transactions, no shares from these exercised options remained held, and the sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025.
CAPRICOR THERAPEUTICS CFO Anthony Bergmann exercised stock options and sold shares in a planned transaction. He exercised options for 25,000 shares of Common Stock at $3.18 per share, then sold 25,000 shares of Common Stock at a weighted average price of $30.1261 per share.
The sale was completed under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following these transactions, Bergmann directly holds 8,223 shares of Capricor Therapeutics common stock.
Capricor Therapeutics, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held on June 4, 2026 at the company’s principal offices.
The Board has fixed the Record Date as April 6, 2026 and is asking shareholders to vote on the election of eight director nominees, ratification of the independent auditor, advisory votes on named executive officer compensation and frequency of say-on-pay votes, and an amendment regarding officer exculpation. The proxy statement includes director biographies, committee compositions, executive compensation disclosure for 2025 and related-party arrangements with Nippon Shinyaku, including upfront and milestone payments tied to distribution of Deramiocel.